AEON Biopharma Long Term Debt

The latest long-term debt for AEON is $2.4M as of March 2026. That compares with $14M in the prior-year period — down 83.6% year over year. Investors often review this figure alongside AEON Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, AEON's long-term debt moved from $14M to $2.4M — a 83.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AEON Biopharma's operating scale or balance-sheet position.

A long-term debt figure of $2.4M for AEON is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AEON's long-term debt ($2.4M), review year-over-year change from $14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.